Search Results - "Clay, T.D."

538P First-line chemoimmunotherapy for metastatic thymic carcinoma by Andreas, V.J., Alexander, M., Rogers, J., Faltys, M., Bowyer, S.E., Warburton, L., Fantoni, A., Clay, T.D., Antippa, P., Solomon, B., John, T.

Get full text

1312MO Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II) by Carcereny, E., Felip, E., Majem, M., Doger de Spéville, B., Clay, T.D., Bondarenko, I., Peguero, J., Cobo Dols, M., Forster, M.D., Ursol, G., Kalinka, E., Garcia Ledo, G.M., Vila Martinez, L., Iams, W., Krebs, M.G., Kefas, J., Efthymiadis, K., Perera, S., Mueller, C., Triebel, F.

Get full text

202P Clinical outcomes to second-line treatment, after failing chemoimmunotherapy, in ES-SCLC by Andreas, V.J., Faltys, M., Alexander, M., Rogers, J., Parakh, S., Bowyer, S.E., Warburton, L., Fantoni, A., Clay, T.D., Arulananda, S., Sullivan, I., Kao, S.C-H., Da Silva, I. Pires, Brown, L.J., Hughes, B.G.M., Itchins, M., Solomon, B., John, T.

Get full text

126P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer (NSCLC) by Frentzas, S., Meniawy, T., Kao, S.C-H., Coward, J., Clay, T.D., Singhal, N., Black, A., Xu, W., Kumar, R., Lee, Y., Lee, G-W., Liao, W., Zhong, D., Shiah, H-S., Chen, Y-M., Gao, R., Wang, R., Zheng, H., Tan, W., Cho, E.K.

Get full text

148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) by Zhang, J., Hussein, M., Kao, S.C-H., Clay, T.D., Singhal, N., Kim, H.R., Cho, E.K., Shim, B., Lee, Y., Lee, G-W., Zhao, J., Yu, Y., Sun, M., Lin, C-B., Yang, T-Y., Chang, G-C., Zheng, H., Tan, W., Spigel, D.R.

Get full text

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients by Rudin, C.M., Pandha, H.S., Gupta, S., Zibelman, M.R., Akerley, W., Day, D., Hill, A.G., Sanborn, R.E., O'Day, S.J., Clay, T.D., Wright, G.M., Jennens, R., Gerber, D.E., Rosenberg, J.E., Ralph, C., Campbell, D.C., Curti, B.D., Schmidt, E.V., Grose, M., Shafren, D.

Get full text

Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations by Clay, T.D., Russell, P.A., Do, H., Sundararajan, V., Conron, M., Wright, G.M., Dobrovic, A., Moore, M.M., McLachlan, S.A.

“…We sought to investigate the frequency of mutations in epidermal growth factor receptor (EGFR) and Kirsten-RAS (KRAS) by each pathological subtype for patients…”
Get full text